Therese Bartholomew Bevers, MD, FAAFP
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
About Dr. Bevers
As the Medical Director of the Cancer Prevention Center (CPC) at The University of Texas MD Anderson Cancer Center, I oversee a comprehensive clinical program providing risk-based cancer screening and personalized cancer risk reduction services to healthy individuals, those at increased risk for cancer and survivors who may be at risk for secondary cancers. I have overseen the development of screening guidelines for MD Anderson that codify the clinical practice in the CPC. In addition, I am the Co-Director of the Clinical Cancer Prevention Research Core that provides the infrastructure for the clinical management and recruitment to a number of cancer screening, chemoprevention and biomarker trials. I have been the PI or Co-PI of numerous studies including Institutional Co-PI for the National Surgical Adjuvant Breast and Bowel Project (NSABP) "Breast Cancer Prevention Trial (BCPT)" and PI for the NSABP "Study of Tamoxifen and Raloxifene (STAR)”, the N01 Consortium “Phase 1b Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with a History of Hormone Receptor-Negative Breast Cancer”. For the STAR Trial, MD Anderson was the largest single site to accrue to the trial. I will oversee the recruitment to the Vanguard Study and provide clinical management of positive results that require further diagnostic evaluation.
In the News
Present Title & Affiliation
Primary Appointment
Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Cancer Prevention Center, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Prevention Outreach Programs, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Breast cancer prevention, screening, diagnosis and survivorship
Education & Training
Degree-Granting Education
| 1987 | The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, MD, Doctor of Medicine |
| 1981 | Texas Woman's University, Denton, TX, USA, BS, Chemistry, Biology |
Postgraduate Training
| 1987-1990 | Family Practice Residency, The University of Texas Health Science Center at San Antonio, San Antonio, TX |
| 1981-1982 | Analytical Chemistry, Texas Woman's University, Denton, TX |
Board Certifications
| 1990 | American Board of Family Practice |
Experience & Service
Other Appointments/Responsibilities
Co-Director, Clinical Cancer Prevention Research Core, Duncan Family Institute for Cancer Prevention and Risk Assessment, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2010 - Present
Institutional Committee Activities
Committee Member, University of Texas Collaboration on Population Health and Improvement, Cancer Survivorship Workgroup, 2021 - Present
Member, Center for Energy Balance in Cancer Prevention and Survivorship Advisory Committee, 2013 - Present
Member, Search Committee, Division Head of Internal Medicine, 2013 - Present
Founding Member, Center for Global Cancer Early Detection, 2013 - 2015
Member, Lung Moonshot-Prevention and Early Detection, 2013 - 2017
Member, Breast and Ovarian Moonshot, 2013 - 2019
Member, Patient History Database Data Access Committee, 2012 - 2019
Chair, Clinical Cancer Prevention Clinical Research Meeting, 2012 - 2017
Member, External Communications Advisory Committee, 2012 - 2013
Member, Comprehensive Cancer Control Planning and Implementation Workgroup, 2011 - 2012
Member, Comprehensive Cancer Control-Liver Workgroup, 2011 - 2014
Clinical Sponsor, Patient History Database Project, Phase II, 2011 - 2013
Member, Comprehensive Cancer Control-Survivorship Workgroup, 2011 - 2013
Co-Chair, Duncan Family Institute Clinical Cancer Prevention Research Core Steering Committee, 2011 - Present
Co-Chair, Integrative Health Working Group, 2011 - Present
Member, Meaningful Use Steering Committee, 2011 - 2012
Member, Integrative Cancer Medicine Steering Committee, 2010 - 2012
Member, PRS Executive Council, 2010 - 2013
Member, PRS Budget and Finance Committee, 2010 - 2012
Co-Chair, Comprehensive Cancer Control - Breast Workgroup, 2010 - 2015
Member, Cancer Survivorship Textbook Workgroup, 2010 - 2015
Member, Clinical Cancer Prevention Faculty Career Development and Promotion Committee, 2010 - 2011
Member, Duncan Family Institute for Cancer Prevention and Risk Assessment Executive Committee, 2009 - Present
Member, Cancer Survivorship Education Subcommittee, 2009 - Present
Member, Faculty Appeals Panel, 2009 - 2011
Member, Duncan Family Institute Premalignant Genome Atlas Program Steering Committee, 2009 - 2011
Member, Comprehensive Cancer Control Strategic Plan Steering Committee, 2008 - 2009
Chair, Cancer Survivorship Community Health Professionals Subcommittee, 2007 - 2016
Member, Breast Program Leadership Committee, 2006 - 2022
Member, Cancer Survivorship Steering Committee, 2006 - Present
Member, Cancer Survivorship Clinical Care Workgroup, 2006 - Present
Member, Multidisciplinary Breast MRI Research Committee, 2006 - 2009
Co-Chair, Multidisciplinary Clinical Management Conference for Benign Breast Lesions, 2004 - Present
Honors & Awards
| 2020 | SBI Honorary Fellow, 2020 SBI/ACR Annual Breast Imaging Symposium |
| 2009 | Who's Who in Medicine and Healthcare |
| 2009 | America's Top Doctors, U.S. News and World Report |
| 2008 | Who's Who in America |
| 2006 | America's Top Doctors, U.S. News and World Report |
| 2004 | Who's Who in Medicine and Healthcare |
| 2004 | Who's Who in the World |
| 2000 | Who's Who in America |
| 2000 | Who's Who in the World |
| 1998 | Who's Who in Medicine and Healthcare |
| 1997 | Physician of the Day, Seventy-fifth Texas Legislature, January 30, |
| 1987 | Distinguished Family Practice Resident, The University of Texas Health Science Center at San Antonio |
| 1984 | Notable Women of Texas |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Asaad M, Offodile AC, Santanelli Di Pompeo F, Bevers TB, Stelly S, Carew LA, Barnea Y, Miranda RN, Butler CE, Clemens MW. Management of Symptomatic Patients with Textured Implants. Plast Reconstr Surg 147(5S):58S-68S, 2021. PMID: 33890882.
- Liao Y, Basen-Engquist KM, Urbauer DL, Bevers TB, Hawk E, Schembre SM. Using Continuous Glucose Monitoring to Motivate Physical Activity in Overweight and Obese Adults: A Pilot Study. Cancer Epidemiol Biomarkers Prev 29(4):761-768, 2020. e-Pub 2020. PMID: 32066620.
- Volk RJ, Mendoza TR, Hoover DS, Nishi SPE, Choi NJ, Bevers TB. Reliability of self-reported smoking history and its implications for lung cancer screening. Prev Med Rep 17:101037, 2020. e-Pub 2020. PMID: 31934536.
- Volk RJ, Lowenstein LM, Leal VB, Escoto KH, Cantor SB, Munden RF, Rabius VA, Bailey L, Cinciripini PM, Lin H, Housten AJ, Luckett PG, Esparza A, Godoy MC, Bevers TB. Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial. JAMA Netw Open 3(1):e1920362, 2020. e-Pub 2020. PMID: 32003822.
- Allweis TM, Strauss L, Malyutin Z, Kapov-Kagan AB, Novikov I, Bevers TB, Iacobelli S, Sandri MT, Bitterman A, Engelman P, Piura B, Rosenberg M, Yahalom G. An autoantibody based protein microarray blood test to enhance the specificity of a negative screening mammogram. Scientific Research 4(1):22-38, 2015.
- Middleton LP, Sneige N, Coyne R, Shen Yu, Dong W, Dempsey P, Bevers TB. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Medicine 3(3):492-9, 2014. e-Pub 2014. PMID: 24639339.
- Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography. Preventive Medicine(62):60-63, 2014. e-Pub 2014. PMID: 24518006.
- Versace F, Engelmann JM, Jackson EF, Slapin A, Cortese KM, Bevers TB, Schover LR. Brain responses to erotic and other emotional stimuli in breast cancer survivors with and without distress about low sexual desire: a preliminary fMRI study. Brain Imaging Behav 7(4):533-42, 2013. PMID: 23955492.
- Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L. Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer 13(6):1-11, 2013. e-Pub 2013. PMID: 24119786.
- Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM. An antibody-based blood test utilizing a panel of biomarkers as a new method for improved breast cancer diagnosis. Biomark Cancer 5:71-80, 2013. PMID: 24324350.
- Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 2013. e-Pub 2013. PMID: 23983047.
- Reddy N, Ninan T, Tabar L, Bevers T. The results of a breast cancer screening camp at a district level in rural India. Asian Pacific J Cancer Prev. e-Pub 2013.
- Guo M, Gong Y, Wang J, Dawlett M, Patel S, Liu P, Bevers TB, Sneige N. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results. Cancer Cytopathol 121(2):79-85, 2013. e-Pub 2012. PMID: 23225501.
- Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) 5(9):1144-54, 2012. e-Pub 2012. PMID: 22827973.
- Mazouni C, Sneige N, Rouzier R, Balleyguier C, Bevers T, André F, Vielh P, Delaloge S. A nomogram to predict for malignant diagnosis of BI-RADS Category 4 breast lesions. J Surg Oncol 102(3):220-4, 2010. PMID: 20740578.
- Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR). Cancer Prev Res (Phila Pa) 3(6):696-706, 2010. e-Pub 2010. PMID: 20404000.
- Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM for the WHIMS and CoSTAR Study Groups. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. Journal of Women's Health 19(3):371-9, 2010. PMID: 20136553.
- Cyrus-David M, King J, Bevers T, Robinson E. Validity assessment of the Breast Cancer Risk Reduction Health Belief scale. Cancer 115(21):4907-16, 2009. PMID: 19637346.
- Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, Shumaker SA. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol 27(31):5144-52, 2009. PMID: 19770382.
- Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, Wang LE. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged </=55 years. Breast Cancer Res Treat 110(2):357-66, 2008. PMID: 17851762.
- Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: The University of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17(5):1096-103, 2008. PMID: 18483331.
- Guo M, Patel SJ, Chovanec M, Jan YJ, Tarco E, Bevers TB, Anderson K, Sneige N. A human papillomavirus testing system in women with abnormal Pap results: a comparison study with follow-up biopsies. Acta Cytol 51(5):749-54, 2007. PMID: 17910345.
- Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?. Breast Cancer Res Treat 102:347-56, 2006. PMID: 17028980.
- Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727-41, 2006. PMID: 16754727.
- Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-62, 2005. PMID: 16288118.
- Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103(6):1122-8, 2005. PMID: 15712375.
- Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23(30):7428 -36, 2005. PMID: 16234510.
- Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA, Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8:2835-42, 2002. PMID: 12231524.
- Singletary, SE, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, Colchin M, Bevers T, Stelling C, Fornage B, Fritsche H, Hittelman W, Kelloff G, Lippman SM. Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and N-[4-Hydroxyphenyl] retinamide. Cancer Epidemiology, Biomarkers and Prevention 9:1087-1090, 2000.
Invited Articles
- Pruthi S, Heisey R, Bevers T. Personalized assessment and management of women at risk for breast cancer in North America. Womens Health (Lond Engl) 11(2):213-224, 2015. PMID: 25776295.
- Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol 4(3):107-12, 2012. PMID: 22590484.
- Krishnamurthy S, Bevers T, Kuerer H, Yang WT. Multidisciplinary considerations in the management of high-risk breast lesions. AJR Am J Roentgenol 198(2):W132-40, 2012. PMID: 22268202.
- Bevers TB. Breast Cancer Prevention: An Update of the STAR Trial. Curr Treat Options Oncol 11(3):66-9, 2010. PMID: 21061192.
- Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer risk reduction. J Natl Compr Canc Netw 8(10):1112-46, 2010. PMID: 20971838.
- Bevers TB. Alcohol and Cancer Incidence in Women. Curr Oncol Rep 11(6):417-419, 2009. PMID: 19840518.
- Bevers TB, Anderson BO, Bonaccio E, Buys S, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T, Yaneeklov T, National Comprehensive Cancer Network. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 7(10):1060-96, 2009. PMID: 19930975.
- Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin 58(6):347-371, 2008. e-Pub 2008. PMID: 18981297.
- Bevers TB. Ultrasound for the screening of breast cancer. Curr Oncol Rep 10(6):527-8, 2008. PMID: 18928668.
- Bevers TB. Raloxifene: An agent for breast cancer prevention. Expert Rev Obstet Gynecol 3(3):277-85, 2008.
- Bevers TB. CT screening for lung cancer. Curr Oncol Rep 9(6):501-2, 2007. PMID: 17991359.
- Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH, Ward JH. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer risk reduction. J Natl Compr Canc Netw 5(8):676-701, 2007. PMID: 17927926.
- Bevers TB. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5(8):719-24, 2007. PMID: 17927929.
- Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 7(16):2301-07, 2006. PMID: 17059385.
- Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: Validated targets in cancer?. J Cell Biochem 92(6):1115-40, 2004. PMID: 15258897.
- Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C, Williams C. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 1(5):242-263, 2003. PMID: 16687096.
- Bevers TB. Breast cancer chemoprevention: current clinical practice and future direction. Biomed Pharmacother 55:559-564, 2001.
- Carlson, R, Barakat R, Bevers T, Daly MB, Edge S, Garber JE, Gradishar W, Mahoney M, Sellin RV, Shapiro C, Singletary E, Theriault R, Ward J, Whittemore A, Williams C, Winer E.. NCCN Practice Guideline: Breast Cancer Risk-Reduction. Oncology 13:241-254, 1999.
- Bevers T. Evidence-based Cancer Screening. Highlights Oncol Pract 16:91-99, 1999.
- Bevers T. How to Perform an Adequate Clinical Breast Examination: A Photographic Guide. Primary Care and Cancer, 1999.
- Singletary, SE, Bevers T, Dempsey P, Farrar B, Garber J, Harris R, Helvie M, Jacobs M, Pass H, Patterson Smith ML, Tarantolo S, Venta LA.. NCCN Practice Guideline: Screening for and Evaluation of Suspicious Breast Lesions. Oncology 12:89-138, 1998.
Manuals, Teaching Aids, Other Teaching Publications
- Baldwin, D, Bevers T, Drugary M, Gullatte MM, Dow KH, Kaur J, O’Donnell J, Palos G, Phillips J. Competencies for Health Professionals: A multicultural perspective in the promotion of breast, cervical, colorectal and skin health. American Nurses Association, Washington, D.C, 1996.
Editorials
- Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient?. JAMA 312(12):1193-4, 2014. PMID: 25247511.
- Bevers TB. Breast awareness: A shift in the paradigm of breast self-examination. J Natl Compr Canc Netw 7(10):1042-3, 2009. PMID: 19930973.
- Bevers TB. Raloxifene: A new paradigm for breast cancer prevention. Breast Diseases: A YearBook Quarterly 18:24-5, 2007.
- Bevers TB, Lippman, SM. Randomized trial of breast self-examination in Shanghai: Methodology and preliminary results. Breast Disease: A YearBook Quarterly 8:308-309, 1998.
- Bevers TB. Breast self-examination an optional screening modality in national comprehensive cancer network breast cancer screening guidelines. Breast Diseases: A YearBook Quarterly 9:230-31, 1998.
Abstracts
- Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Patients' reactions to a decision aid about lung cancer screening with low-dose spiral computed tomography: an uncontrolled trial. J Clin Oncol 31(suppl; abstr 1564), 2013.
- Dawlett M, Kologinczak T, Wang J, Sneige N, Bevers T, Guo M. Three-year follow-up for women 30 years and older with negative pap and negative hybrid capture 2 HPV DNA testing results. Journal of the American Society of Cytopathology 1(1):S40, 2012.
- Wang J, Kologinczak T, Dawlett M, Bevers T, Sneige N, Guo M. Risk of CIN2+ in women 30 Years and older with negative pap and positive hybrid capture 2 HPV DNA testing results. Journal of the American Society of Cytopathology 1(1):S52, 2012.
- Crew KD, Lippman S, Hershman DL, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArhtur H, Vornik L, Cornelison T.. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer. Cancer Prevention Research 4(10 Supplement):CN06-02, 2011.
- Morrow PKH, Bevers TB, Zandstra F, Russell L.. Multidisciplinary care of the breast cancer survivor: an innovative approach. Breast Cancer Symposium. J Clin Oncol 29(suppl 27; abstr 206), 2011.
- Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L, Harris S, Adeyinka OW, Fritshe HA, Bast RC. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement), 2010.
- Crew KD, Brown P, Greenlee H, Bevers T, Arun B, Hudis C, McArthur HL, Vornik L, Cornelison TL, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement), 2010.
- Olson AL, Bevers T, Guzman M, Theriault RL, Hortobagyi GN, Hahn KM. Cervical and colorectal cancer screening among breast cancer (BrCa) survivors followed in either a breast center (BC) or a breast survivorship clinic (SvC) at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol (ASCO Meeting Abstracts) 27:No. 15S(May 20 Supplement), 2009.
- Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc:995, 2007. PMID: 18694095.
- Dong W, Berry D, Bevers T, Kau Shu-Wan, Hsu L, Theriault R, Shen Y. Prognostic role of detection method in breast cancer: M.D. Anderson Cancer Center experience. Proceedings of the American Association for Cancer Research Meeting, Los Angeles, 2007.
- Wickerham DL, Constantino JP, Vogel V, Cronin W, Cecchini R, Atkins J, Bevers T et al. The study of tamoxifen and raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study. J Clin Oncol (ASCO Meeting Abstracts) 24:No. 18S(June 20 Supplement), 2006.
- Cristofanilli, M, Yamamura Y, Kau SW, Bevers TB, Strom SS, Patangan MG, Hsu LM, Krishnamurthy S, Hortobagyi GN. Thyroid hormones and breast cancer: primary hypothyroidism is associated with a reduced incidence of primary breast cancer. Proceedings of the American Association for Cancer Research 44:66, 2003.
- Sun, CC, Bodurka DC, Lu KH, Efron B, Andersen R, Bevers TB, Gershenson DM, Bast RC. Perceptions of OVCA risk and screening: differences between women with a history of breast cancer (WHxBr) and women with no history of breast cancer (WnoBr). Gynecol Oncol, 88:239, 2003.
- Boling, W, Carmack Taylor CL, Shinn EH, Dijk F, Zilstra R, Bevers TB, Basen-Engquist K. Breast cancer survivors and physical activity: Accuracy of self-report with surgeon general’s recommendations. Annals of Behavioral Medicine 24:S163, 2002.
- Wang, S, Bevers TB, Krishnamurthy S. Changes in cervicovaginal smears of women receiving tamoxifen for chemoprevention of breast cancer compared with those of women taking placebo. Mod Path 15:91A, 2002.
- Singletary, SE, Lieberman R, Binkley S, Atkinson EN, Sneige N, Sahin A, Bevers T, Stelling c, Fornage B, Fritsche H, Hittelman W, Kelloff GJ, Lippman SM. Novel translational model for breast cancer chemoprevention study: presurgical intervention with tamoxifen and 4-HPR. Proceedings of the American Society of Clinical Oncology, 35th Annual Meeting, Atlanta, GA,:84a, 1999.
Book Chapters
- Bevers T. Screening for Second Primary Cancer. In: Advances in Cancer Survivorship Management, MD Anderson Cancer Care Series. Springer: New York, 299-321, 2015.
- Bevers T, Brown PH, Maresso KC, Hawk ET. Cancer Prevention, Screening and Early Detection. In: Abeloff's Clinical Oncology. Fifth Edition. Elsevier: Philadelphia, PA, 322-59, 2014.
- Bevers T. Breast Self-Examination: A Changing Paradigm. In: Advanced Therapy of Breast Disease, Third Edition. People's Medical Publishing House: Shelton, CT, 139-52, 2012.
- Bevers TB. Chapter 86: Clinical Management of the Patient at Increased or High Risk. In: The Breast: Comprehensive Management of Benign and Malignant Diseases, Fourth Edition. Saunders: Philadelphia, PA, 1381-92, 2009.
- Bevers T, Bedrosian I. Chapter 72: Prevention: Prophylactic Mastectomy and Chemoprevention. In: Advanced Therapy for Surgical Oncology. BC Decker, Inc: Hamilton, Ontario, Canada, 588-96, 2008.
- Bevers TB. Primary Prevention and Screening for the Early Detection of Breast Cancer. In: Breast Cancer. M.D. Anderson Cancer Center. Springer-Verlag: New York, 27-55, 2007.
- Bevers T. Breast Self-examination. In: Advanced Therapy of Breast Disease, Second Edition. B.C. Decker, Inc.,, 193-201, 2004.
- Coyne RL, Bevers T. Counseling about Risk Management. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publishers: Sudbury, Mass, 126-45, 2003.
- Lazzaro MV, Bevers T. Hormone Replacement Therapy. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publisher: Sudbury, Mass, 99-118, 2003.
- Mizell V, Bevers T. Development of a Risk Assessment Clinic. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and managemen. Jones and Bartlett Publishers: Sudbury, Mass, 41-54, 2003.
- Bevers T. Primary Prevention and Screening for the Early Detection of Breast Cancer. In: M.D. Anderson Cancer Care Series. Springer-Verlag: New York, 21-54, 2001.
- Bevers T. Diagnosis of Palpable Breast Masses. In: Advanced Therapy of Breast Disease, First Edition. B. C. Decker, Inc: Hamilton Ontario, 73-82, 2000.
- Bevers T, Levin BL. Colorectal Cancer: Population Screening and Surveillance. In: Evidence Based Gastroenterology and Hepatology. BMJ Books: London, 230-240, 1999.
Books (edited and written)
- Vogel VG, Bevers T, Editors. Handbook of breast cancer risk assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publishers: Sudbury, Mass, 2003.
Letters to the Editor
- Mac Bride MB, Pruthi S, Bevers T. The evolution of breast self-examination to breast awareness. Breast J 18: 641-643, 2012.
Grant & Contract Support
| Title: | STAR Community Outreach Coordinator |
| Funding Source: | NSABP |
| Role: | Principal Investigator |
| Title: | The Use of Stimulated Whole Saliva as a Diagnostic Test for the Detection of Breast Cancer in Women |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-Principal Investigator |
| Title: | Statistical Methods for Breast Cancer Prevention and Treatment Studies and Therapeutic Response |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial |
| Funding Source: | Foundation for Informed Medical Decision Making-(FIMDM) |
| Role: | Co-Investigator |
| Title: | Early Detection of Epithelial Ovarian Cancer |
| Funding Source: | National Cancer Institute-DHHS-NIH-P50 |
| Role: | Collaborator |
| Title: | The Use of Saliva as Diagnostic Fluid for the Detection of Breast Cancer in Women |
| Funding Source: | Assurance Biosciences, Incorporated |
| Role: | Principal Investigator |
| Title: | The Use of Simulated Whole Saliva as a Diagnostic Test for the Detection of Breast Cancer |
| Funding Source: | University of Texas Dental Branch-Houston |
| Role: | Collaborator |
| Title: | Blood Test for Breast Cancer Associated Auto Antibodies |
| Funding Source: | Eventus Diagnostics, Inc |
| Role: | Principal Investigator-MDACC |
| Title: | An Integrated Professional Oncology Curriculum for Texas Primary Care Professionals: Improving Care and Enhancing Quality of Life for Breast, Colon and Prostate Cancer Survivors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Patient Centered Outcome Research in the Elderly |
| Funding Source: | The University of Texas Medical Branch at Galveston |
| Role: | Co-Principal Investigator |
| Title: | Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Title: | A Randomized Phase II Window-of Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions |
| Funding Source: | Incyte Corporation/Johns Hopkins University |
| Role: | Co-Principal Investigator |
| Title: | 2020-0724: DROPLET-BRC study |
| Funding Source: | Preferred Medicine, Inc |
| Role: | Collaborator |